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Background: Self-expandable metallic stents (SEMS) are employed as the preferred nonsurgical palliative treatment 
for gastric outlet obstruction due to malignancies. Metallic stents are often employed to treat malignant anastomotic 
obstructions after surgical interventions as esophagojejunostomy, gastrojejunostomy and esophagogastrojejunostomy. 
Methods: This case series reports prospectively the clinical outcomes of SEMS in the palliative care of malignant 
anastomotic strictures caused by the recurrence of gastric cancer following gastric surgery as oncological curative 
treatment, in a series of nine consecutive patients, treated between January 2009 and December 2012 in our center. 
Results: Nine patients (M:F=8:1) were enrolled in the study. The operation was a total gastrectomy with 
esophagogastrojejunostomy (n=4), subtotal gastrectomy with Billroth-II reconstruction (n=3), and subtotal gastrectomy 
with esophagogastrostomy (n=2) .The technical success rate was 88.9%, and the clinical success rates was 88,9 %. The 
reobstruction of the stent, due to the ingrowth of the tumor, occurred in 1 patient (11,1%) within 1 month after stent 
placement. The migration of the stent occurred after the placement of a covered stent in 1 patient who underwent a 
subtotal gastrectomy (with Billroth-II reconstruction). A case of partial stent dislodgement was easily treated with the 
placement of a second stent. The median survival period was 180 days (range, 30-240 days) and the median stent 
patency was 45 days (range, 30-90 days). Conclusions: Although the number of the patients treated with SEMS results, 
in this series, almost small to certainly judge the safety and feasibility of SEMS, we believe that the endoscopic 
insertion of SEMS seems to be a safe, easily feasible, and effective treatment in the palliative care of malignant 
anastomotic strictures caused by the recurrence of gastric cancer following gastric surgery. The technical and clinical 
success, and the onset of complications of this procedure are influenced by several factors, such as the type of 
anastomosis, the technical features of the stent, and the extent of the underlying tumor. 
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Introduction 
Self-expandable metallic stents (SEMS) are used as the 
preferred nonsurgical palliative treatment for malignant 
gastric outlet obstruction [1]. Metallic stents are often 
employed to treat malignant anastomotic obstructions after 
surgical interventions as esophagojejunostomy, 
gastrojejunostomy and esophagogastrojejunostomy. High 
mortality and morbidity following palliative surgery is 
observed in patients with advanced disease, poor general 
conditions, prolonged hospitalization, and digestive tract 
dysfunctions, such as delayed gastric emptying or bilious 
vomiting [2].  
Few data are available about the use of SEMS for the 
nonsurgical palliative treatment for recurrent malignant 
gastric outlet obstruction [3-11]. To our knowledge, few 
studies focused on endoscopic placement of SEMS in the 
recurrence of anastomotic strictures [11-15]. In this setting, the 
clinical outcomes and complications might differ according 
to the surgical technique because of the different anastomotic 
angle or different anatomical alterations during surgery. 
Aim of our study is to report prospectively the clinical 
outcomes of SEMS, in the palliative care of anastomotic 
strictures, due to the recurrence of gastric cancer following 
gastric surgery as oncological curative treatment, in a series 
of nine consecutive patients. 
Methods 
Nine consecutive patients (M:F = 8:1, median age 76 
years, range 48-85 years), who presented a post-operative 
anastomotic strictures, due to the recurrence of gastric cancer 
and underwent endoscopic SEMS placement from January 
2009 to december 2012, were included in the study. All 
patients presented with a symptomatic obstruction, as 
confirmed by a median gastric outlet obstruction score 
(GOOS) >1. 
The recurrence of gastric cancer, cause of the obstruction, 
was confirmed, in all patients, by experienced pathologists. 
No patient was a surgical candidate, due to the presence of 
metastatic disease or due to medical comorbidities. 
The exclusion criteria were the following: (a) 
asymptomatic or mildly symptomatic patients; (b) patency of 
the malignant anastomotic stricture, with regard to an adult 
endoscope; (c) clinical evidence of peritonitis. Before the 
endoscopic procedure, an abdominal computed tomography 
(CT) scan was performed, in order to exclude multiple 
strictures. 
The type of surgery performed was a total gastrectomy 
with esophagogastrojejunostomy in 4 patients, subtotal 
gastrectomy with Billroth-II reconstruction in 3 patients, and 
subtotal gastrectomy with esophagogatrostomy in 2 patients. 
The margins of the proximal and distal section were, after 
surgical intervention, histologically free from tumor invasion 
[12]. 
NITI-S stents (Taewoong, Seoul, Korea, n=2), WallFlex 
duodenal stents (Boston Scientific, Boston, Mass, USA, n=3) 
and Evolution esophageal partially covered stents (Cook 
Medical Endoscopy, Bloomington, Ind, USA, n=4) were 
used. The degree, lenght and location of the stenosis were 
evaluated using an endoscopic procedure or contrast media 
radiographic study, prior to stent placement. Two out of nine 
stents were fully covered, five out of nine were uncovered, 
and two out of nine were partially covered.  
The Niti-S stent (Taewoong Medical, Seoul, Korea) has a 
double layer configuration over its entire length, consisting 
of an inner polyurethane layer over its complete length and 
an outer uncovered nitinol wire. The stent flares to 26 mm at 
its proximal and distal ends with a body diameter of 18 mm. 
It is available in three lengths: 9, 12, and 15 cm. The stent is 
delivered in a compressed form inside an introducer sheath 
[16]. 
The WallFlex duodenal stent (Boston Scientific Co., 
Natick, Mass., USA) is an uncovered SEMS composed of 
nitinol. It has a flare at the proximal end to minimize the risk 
of migration and looped ends to reduce the risk of tissue 
injury. The diameter is 22 mm at the body and 27 mm at the 
flared proximal end. This stent is available in 60-, 90-, or 
120-mm lengths [17]. 
Evolution (Cook, Bloomington, Ind, USA) is available as 
a partially or fully covered SEMS. The stent is encased with 
silicone on its exterior and interior surfaces to prevent tumor 
in growth. A unique feature of Evolution delivery system is 
that it enables a controlled release and recapturability feature 
with a “point of no return” indicator. With each squeeze of 
the stent system’s trigger-based introducer, a proportional 
length of the stent is deployed or recaptured [18]. 
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The patients usually resumed a water or a liquid diet 24 h 
after stent placement, then they started a soft or solid diet 
after the follow up X-ray showed full extension of the stent. 
After the placement of the stent, a chemotherapy (based on 
the judgement of the oncologist) was administered when the 
oral intake improved and the Eastern Cooperative Oncology 
Group performance status was ≤ 2 (graded as follows: 0 = 
normal activity, 1 = symptoms but ambulatory, 2 = in bed 
less than 50% of time, 3 = in bed more than 50% of time, and 
4 = totally bedridden). After stent placement, palliative 
chemotherapy was performed in two patients (22, 2 %) [9]. 
The outcome of the stent was evaluated according to: (1) 
technical success and clinical success; (2) complications; (3) 
stent patency. 
The technical success was defined as the successful 
placement of a stent in the correct location and the 
confirmation of its patency using both the endoscopy and the 
fluoroscopy with oral contrast. The clinical success was 
defined as the improvement or the resolution of the 
obstructive symptoms and oral intake 1 to 3 d after the 
placement of the stent. The degree of oral intake was 
assessed using the Gastric Outlet Obstruction Scoring 
System as follows: 0 = no oral intake; 1 = exclusively liquid 
diet; 2 = exclusively soft solids diet; 3 = full diet possible. 
A primary stent dysfunction was defined as the 
impossibility to resume an oral intake after stent placement. 
The stent patency time was defined as the duration 
between the initial stent insertion and the recurrence of 
obstructive symptoms due to the occlusion of the stent [12]. 
All patients were followed up to estabilish their clinical 
outcomes until they died or the stent did not function, such as 
by dislodgement or occlusion by tumor in growth or 
overgrowth. The data were reported from the hospital 
records. The status of oral food intake was monitored at 1 
month intervals on an outpatient basis. A follow-up barium 
study or endoscopy was performed only if obstructive 
symptoms recurred in order to determine stent occlusion or 
dislodgement [12]. 
Results 
-Technical and clinical success  
Endoscopic stent placement was technically successful in 
eight out of nine patients (88, 9%). Clinical success (GOOS: 
3) was achieved in eight out of nine patients (88, 9 %) 
-Complications 
There was no procedure-related mortality. Only in one 
patient who underwent a distal gastrectomy (with 
Billroth-reconstruction), the uncovered stent did not expand 
completely and was compressed by the tumor mass until 5 
days after stent insertion. The symptoms were not improved. 
However, he refused further treatments and was treated with 
supportive care. 
The recurrence of symptoms of an obstruction was 
observed in 2 patient (22,2%) as a result of tumor ingrowth 
(n = 2) within 1 month after stenting. The reobstruction rate 
(1/4 vs 1/5) of a covered (fully and partially) stent and 
uncovered stent, and stent patency duration [45 days (range, 
30-90) for the covered stent vs 45 days (range, 30-90) for the 
uncovered stent] were similar. 
Tumor overgrowth did not occurred (0%). Tumor 
ingrowth occurred in two patients (22, 2%) who underwent a 
Table 1. Patients' features 
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subtotal gastrectomy with Billroth-II reconstruction, in 
whom an uncovered stent was placed and who underwent to 
esophago-jejunostomy, in whom a partially covered stent 
was placed, respectively. Interestingly, tumor in growth 
occurred in patients with signet ring cell gastric 
adenocarcinoma. The patients were successively treated 
conservatively, because of the refusal of further invasive 
treatments. 
Partial stent dislodgement to the more distal side of the 
efferent loop occurred in one patient (11, 1%), two days after 
stent insertion. The patient was treated by placing a second 
stent into the previous stent, with subsequent clinical 
improvement. 
Complete stent dislodgement occurred at 15 days in one 
patient with esophago-gastrostomy (11, 1%). The migrated 
stent was detected into the stomach. He presented with 
abdominal pain, and was treated with elective 
esophagojejunostomy. 
Further complications after SEMS insertion, as fever, 
aspiration pneumonia, bleeding and perforation were not 
observed. 
-Survival 
None of the patients was lost during the follow-up period, 
but all the nine patients died. The median survival period was 
180 days (range, 30-240 days) and the median stent patency 
was 45 days (range, 30-90 days).  
Discussion 
SEMS placement has emerged as a nonsurgical palliative 
treatment and has shown promising results in the setting of 
the palliative care [19,20]. A SEMS has several clinical 
advantages, compared with surgery, such as rapid resumption 
of oral intake, shorter hospital stay and rapid improvement in 
the quality of life in gastric obstruction due to recurrent 
gastric cancer [21,22].  
In this series, the technical success rate was 88, 9 %, 
which is comparable to those with a primary malignant 
gastric outlet obstruction (83%-100%) [20]. The dietary intake 
improved in 88, 9% of patients after stent placement, which 
is comparable to the clinical success rate of SEMS insertion 
in a malignant gastric outlet obstruction (75%-85%) [21]. The 
improvement in symptoms after SEMS insertion in the 
anastomotic stricture caused by the recurrence of gastric 
cancer was reported to be 80%-90% (3-8). In our series, a CT 
scan performed prior to the stent placement excluded 
concealed obstructions. In the series reported by Cho and 
coworkers [12], five out twenty patients whose symptoms did 
not improve had another single stricture at the small intestine 
or colon, or ileus by peritoneal dissemination. For this 
reason, the authors suggested that a study of the distal bowel 
loop using a CT scan or barium study before stent placement 
might be useful in order to exclude a concealed obstruction.  
A further occlusion of the stent, due to tumor in growth, 
occurred in two patients (22, 2%) within 1 month after stent 
placement. A previous study reported that early restenosis 
within 1 month tended to occur more frequently in 
postoperative anastomosis than a gastric outlet obstruction 
caused by primary cancer (4/6 vs 2/6, P < 0.01) [23]. The 
covered stents had the merit of less frequent reobstruction by 
tumor ingrowth [24]. However, in this study, the reobstruction 
rate and stent patency duration of covered stents and 
uncovered stents were similar. The incidence of stent 
reobstruction in recurrent anastomotic stricture after gastric 
surgery was reported to be 0%-17% [3-8]. Most studies used 
covered stents. In two studies using uncovered stents, Lee 
and coworkers [6] reported that one out of 4 patients had 
tumor ingrowth, and Song and coworkers [7] reported a 50% 
stent reobstruction rate within 2 weeks of stent placement. A 
prospective, randomized, comparative study to determine 
which stent is favorable in this situation will be needed. 
Table 2.Complications associated with stent placement 
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One case of stent dislodgement (11,1%) was encountered 
in patients who underwent a subtotal gastrectomy with 
Billroth-II reconstruction and had a covered stent inserted. A 
complete stent migration occurred at 15 days in one patient 
with esophago-gastrostomy (11,1%). The migrated stent was 
detected into the stomach. He presented with abdominal pain, 
and was treated with elective esophagojejunostomy. The 
incidence of stent dislodgement was reported to be 0%-16% 
in studies using a covered stent in an anastomotic stricture in 
various types of gastric cancer surgery [3-8]. The surgical 
technique could influence the percentage of dislodgement. 
The relatively acute angle between anastomosis and the 
efferent loop in gastrojejunostomy compared with the 
relatively obtuse angle in esophagojejunostomy or 
gastroduodenostomy, the radial force of the stent in the 
angulated loop, or the use of a covered stent may influence 
stent migration [12]. 
In this study, the 30-day mortality was 0%. The median 
survival period was 180 days (range, 30-240 days) and the 
median stent patency was 45 days (range, 30-90 days). Since 
the median survival in an anastomotic obstruction is similar 
to that in a primary malignant gastric outlet obstruction, 
strategies to prolong stent patency and avoid the need for 
further intervention are useful in patients with malignant 
recurrence, particularly those with a good performance status 
or who are expected to have a prolonged survival. 
In the study performed by Cho and coworkers, the authors 
showed that the technical and clinical success of SEMS 
placement for anastomotic strictures due to the recurrence of 
gastric cancer were 100% and 70%, respectively. In this 
study, clinical failure was due to small bowel or colon 
stricture in addition to anastomotic stricture. Stent migration 
(15%) was reported in patients who underwent subtotal 
gastrectomy with Billroth-II reconstruction and had a 
covered stent placed [12]. 
Song and coworkers [13] placed SEMS in 39 patients with 
malignant anastomotic obstructions after gastrojejunostomy 
and reported their results. In their series, stent placement was 
technically achieved in all patients, and 35 patients (90%) 
obtained relief from their obstructive symptoms. However, 
aspiration pneumonia, stent migration, and reobstruction 
occurred in 2, 4, and 2 patients, respectively, with a total 
complication rate of 23.1%. Kim and coworkers [14] also 
reported the results for 39 postgastrectomy patients who 
underwent SEMS placement. The technical success rate was 
92% and the total complication rate was 44%. In the series of 
Kim and coworkers [14], 2 patients suffered from 
stent-associated perforation. On the basis of previous studies, 
it was supposed that SEMS placement is more risky in 
postgastrectomy patients than in patients with unresectable 
primary gastric cancers, although the treatment is technically 
feasible [25] 
Our study presents some limitations. First, the small 
number of patients and the use of several types of SEMS 
could affect the representativeness of the studied population. 
Second, the fact that no patient was a candidate for surgery 
may creates a selection bias. However, in this study we 
represent our personal experience in this subset of patients, 
comparing it with the data available from the scientific 
literature. 
Conclusions 
The endoscopic placement of a SEMS seems to be a safe, 
easily feasible, and effective treatment in the palliative care 
of malignant anastomotic strictures caused by the recurrence 
of gastric cancer following gastric surgery. The technical and 
clinical success, and the onset of complications of this 
procedure are influenced by several factors, such as the type 
of anastomosis, the technical features of the stent, and the 
extent of the underlying tumor (which can influence, for 
example, the presence of concealed obstructions). 
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